VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | ABBV-744 and Mivebresib: BET inhibitors in myelofibrosis

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses two Phase Ib studies (NCT04454658, NCT04480086) evaluating the safety and efficacy of the BET inhibitors ABBV-744 and mivebresib in myelofibrosis patients. ABBV-744 and mivebresib will be used in multiple cohorts of patients undergoing salvage therapy, including those previously treated with ruxolitinib and those having a suboptimal response to their current treatment. These studies will also investigate ABBV-744 and mivebresib in combination with ruxolitinib or navitoclax. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

John Mascarenhas, MD, has done consultancy work with Celgene/BMS, Prelude, Galecto, Promedior, Geron, Constellation and Incyte, and has received research funding from Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen and PharmaEssentia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter